Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科倫博泰生物醫藥股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6990） 自願公告 核心產品TROP2 ADC蘆康沙妥珠單抗(sac-TMT) 獲 國 家 藥 品 監 督 管 理 局 批 准 第 四 項 適 應 症 上 市， 用於治療2L+ HR+/HER2-乳腺癌 四 川 科 倫 博 泰 生 物 醫 藥 股 份 有 限 公 司（「本公司」）董 事（「董 事」）董 事 會（「董 事 會」）欣 然 宣 佈，近 日，本 公 司 靶 向 人 滋 養 細 胞 表 面 抗 原2(TROP2)的抗體 偶聯藥物(ADC)蘆 康 沙 妥 珠 單 抗（sac-TMT，亦稱SKB264/MK-2870）（佳 泰 萊®） 的一項新增適應症上市申請 已獲中國國家藥品監督管理局(NMPA)批 准， 用於治療既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療 的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰 性（HER2-）（免 疫 組 織 化 ...

Group 1 - The core point of the article is that Eli Lilly's drug Tirzepatide is projected to achieve sales of $36.507 billion in 2025, marking it as the "king of drugs" for that year, with expectations to maintain this position for several years [1] - According to Evaluate, approximately half of the top ten global drugs by sales in 2030 are expected to be GLP-1 class drugs [2] - The weight loss sector has become a strategic focus for major pharmaceutical companies (MNCs), with significant business development (BD) and mergers and acquisitions (M&A) activity anticipated this year [3] Group 2 - Major pharmaceutical companies are heavily investing in the weight loss sector, with Eli Lilly expecting Orforglipron to receive approval in Q2 2026 and ongoing clinical trials for other drugs [3] - Recent transactions in the weight loss sector include a $100 million upfront payment from Roche for a specific oral GLP-1 agonist patent and a strategic collaboration between CSPC and AstraZeneca worth up to $18.5 billion [4] - New directions in the weight loss market, such as oral small molecules and ultra-long-acting GLP-1 drugs, present potential investment opportunities, with companies like Singlomd, Hengrui Medicine, and others identified as relevant targets [4]

Palantir涨11.4%，财报业绩和指引双超市场预期。半导体测试公司泰瑞达涨6.3%，Q4业绩强劲增长。 Palladyne AI涨10.9%，与美国国防主承包商签订合同。PayPal跌17.8%，Q4利润不及预期并任命新 CEO。默沙东跌1.7%，2026年销售额指引不及预期。 来源：滚动播报 ...

国家统计局：2026年1月份中国制造业采购经理指数为49.3% 比上月下降0.8个百分点 国家统计局、中国物流与采购联合会31日发布2026年1月份中国采购经理指数。数据显示，1 月我国制造业市场需求有所收紧，但企业生产保持扩张态势，产业结构继续优化；服务业运行 态势相对稳定，企业预期持续向好。2026年1月份中国制造业采购经理指数为49.3%，比上月 下降0.8个百分点。1月份装备制造业采购经理指数为50.1%，高技术制造业采购经理指数为 52%，装备制造业和高技术制造业稳中向好发展，制造业产业结构持续优化。 北京经济技术开发区：推进数模混合、存算一体等芯片架构研发创新 延伸场景定义芯片、行 业专用芯片、使能软件等产业链条 北京经济技术开发区管理委员会印发《关于进一步加快建设全域人工智能之城的实施方案 （2026—2027年）》。其中提到，夯实智能原生基础能力。发挥集成电路制造能力优势，推 动"设计-制造-封测-算力"一体化协同发展，牵引算力基础设施与高性能智算产业持续迭代。推 进数模混合、存算一体等芯片架构研发创新，延伸场景定义芯片、行业专用芯片、使能软件等 产业链条。推动通用与垂类模型协同发展，加快认知 ...

Core Viewpoint - Pfizer has unveiled a significant R&D plan for 707/PF'4404 (PD-1/VEGF) in collaboration with 3SBio, with an accelerated pace and breadth beyond expectations, aiming to initiate four global Phase III clinical trials by 2026 across five major first-line indications [1][2] Group 1: Clinical Development - Pfizer plans to launch four Phase III clinical trials in 2026 targeting first-line squamous/non-squamous NSCLC, mCRC, endometrial cancer, and urothelial carcinoma [2] - The company has already completed the first patient enrollment for Phase III trials targeting first-line NSCLC and mCRC, as well as Phase II/III trials for first-line ES-SCLC [2] - Pfizer will also initiate Phase III clinical studies combining 707 with various ADCs, such as Padcev for first-line treatment of urothelial carcinoma [2] Group 2: Competitive Landscape - Four multinational corporations (MNCs) are competing in the PD-(L)1/VEGF space, including Pfizer, BMS, Merck, and AbbVie, with Pfizer expected to stand out due to its "speed, breadth, and depth" advantages [2] - BMS and BioNTech have announced extensive clinical plans, but their progress in core indications like first-line NSCLC and mCRC lags behind Pfizer [2] Group 3: Pipeline and Financials - 3SBio is increasing R&D investments with multiple pipelines expected to yield clinical data, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1) in Phase II trials in China [3] - The core business fundamentals of 3SBio remain robust, with projected revenue of approximately 4.2 billion yuan in 2025, including 2.89 billion yuan from the upfront payment for 707 licensing [3] - Excluding the upfront payment, the internal business revenue of 3SBio is estimated to grow by about 9% year-on-year [3] Group 4: Investment Rating - The company maintains a "Buy" rating with a target price of 37.43 HKD, supported by an estimated net cash position of approximately 13 billion yuan [4] - Confidence in 707 becoming a global blockbuster is reaffirmed due to Pfizer's unexpected clinical advancement [4]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint application [10][11] - The year 2026 is identified as a critical year for the combination of IO and ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological cancers [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III clinical trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and various cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody and oral CELMoD therapies, with significant data catalysts expected in 2026 [32][33] - Roche is focusing on breast cancer, with its oral SERD Giredestrant expected to be approved soon [37][38] Section 2: The Year of IO+ADC Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO+ADC combinations are competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, highlighting their potential in the oncology sector [11][56]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four Phase III trials in 2026 targeting five major indications. This development is expected to position Pfizer favorably in the competitive landscape of next-generation cancer immunotherapy [1][8]. - The collaboration between Pfizer and the company is anticipated to unlock significant global value for 707/PF'4404, serving as a key catalyst for the company's upward trajectory [1][8]. - The company is also increasing its R&D investments, with multiple pipelines expected to yield clinical data soon, enhancing the potential for external licensing opportunities [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. Projections for FY24A and FY25E are RMB 9,108 million and RMB 17,972 million, respectively, indicating a significant growth trajectory [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, reflecting a decline of 19.1% year-on-year, but is expected to rebound to RMB 2,090 million in FY24A and surge to RMB 9,741 million in FY25E, marking a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY25E is projected at RMB 3.84, with a price-to-earnings (P/E) ratio of 5.6, indicating a strong valuation relative to earnings [2][15]. Market Position and Shareholder Structure - The company's market capitalization stands at HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6%, indicating a concentrated ownership structure [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs (antibody-drug conjugates) as a unique advantage [1][8]. - The company has several promising candidates in its pipeline, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1), which are currently in Phase II trials in China [8][12]. Valuation and Forecast Adjustments - The report adjusts the financial forecasts for FY25E and FY26E, reflecting a slight increase in revenue expectations due to the anticipated success of the 707 program [12][13]. - The DCF valuation analysis estimates a per-share value of HKD 37.43, based on a weighted average cost of capital (WACC) of 10.11% and a perpetual growth rate of 2.0% [13][14].

Core Viewpoint - Companies that rely on a single dividend and lack core technology will ultimately struggle to sustain themselves in the long run [4][30]. Group 1: Company Overview - Zhifei Biological, once a leading vaccine company in China, is facing a significant downturn, with projected net losses of 10.698 billion to 13.726 billion yuan for 2025, marking a year-on-year decline of 630% to 780% [5][6]. - The company’s revenue skyrocketed from 4 billion yuan in 2016 to 52.92 billion yuan in 2023, with net profits reaching 7.915 billion yuan, showcasing a rapid growth trajectory [12]. - However, the company’s reliance on agency business has proven to be a fragile foundation, leading to a severe profit crisis as market dynamics shifted [13][15]. Group 2: Financial Crisis - By 2025, Zhifei Biological's revenue is expected to plummet to 26.07 billion yuan, with a net profit of only 1.991 billion yuan, reflecting a nearly 75% year-on-year decline [14]. - The company is experiencing a liquidity crisis, with total liabilities of 16.786 billion yuan and a significant short-term debt of 10.318 billion yuan, while cash reserves are only 2.498 billion yuan, resulting in a funding gap exceeding 7.8 billion yuan [18][20]. - To alleviate inventory pressure, Zhifei Biological has initiated promotional activities and is attempting to optimize its debt structure through bond issuance, but the process has faced obstacles due to unexpected losses [19][20]. Group 3: Wealth and Market Dynamics - The wealth of the Jiang Rensheng family has drastically decreased from 140 billion yuan in 2021 to 42 billion yuan in 2025, a loss equivalent to the combined market value of two leading listed companies in Chongqing [17]. - The stock price of Zhifei Biological has also dropped from 360 billion yuan to 41 billion yuan, reflecting the company's declining market position [18]. - The rise of Zhang Xinghai and Yan Min, who have transitioned to become the new wealth leaders in Chongqing through advancements in the smart automotive sector, highlights a shift in the local business landscape [24][28]. Group 4: Industry Trends - The challenges faced by Zhifei Biological are indicative of a broader trend in the vaccine industry, where domestic companies are increasingly breaking the monopoly of foreign firms, leading to intensified competition [30]. - The shift from reliance on agency business to a focus on independent innovation is becoming essential for survival in the evolving market [31][32].

Core Insights - The JPMorgan Global Healthcare Conference serves as a significant platform for the biopharmaceutical industry, influencing capital flows and industry dynamics for the year ahead [1] - This year's conference highlighted the increasing presence of Chinese biotech companies, marking a shift from being mere spectators to key players in the global market [2][3] Group 1: Chinese Biotech Companies - Seven Chinese companies, including WuXi AppTec and BeiGene, presented on the main stage, with an additional 17 companies showcasing in the Asia-Pacific session [2] - The transformation of Chinese companies from the periphery to the center of the conference reflects their substantial innovation value, evidenced by numerous licensing deals announced during the event [3] Group 2: Licensing Deals and Collaborations - Notable licensing agreements included a $650 million upfront payment from AbbVie to Rongchang Biopharma for the global rights to its PD-1/VEGF dual-specific antibody, with a total potential deal value of up to $5.6 billion [3] - Other significant collaborations involved Zhongsheng Peptide and Sai Shen Pharmaceutical partnering with Novartis, with the latter's deal valued at approximately $1.665 billion [3] Group 3: MNCs and Market Dynamics - The cautious approach of multinational corporations (MNCs) towards acquisitions is driven by the impending "patent cliff," with over $320 billion in market potential products set to lose patent protection in the next decade [3][5] - MNCs are increasingly favoring "asset-based acquisitions" over full company buyouts, allowing them to efficiently acquire core assets without the burdens of integrating entire companies [4] Group 4: AI in Drug Development - AI's integration into drug development emerged as a central theme, with Eli Lilly and NVIDIA announcing a partnership to establish a $1 billion AI innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry [5][6] - The acquisition of Modella AI by AstraZeneca further emphasizes the growing importance of AI in enhancing drug discovery and clinical development processes [6] Group 5: Future Outlook - The 2026 JPM conference is expected to reflect a new paradigm where Chinese innovation becomes essential, and AI evolves from a supportive tool to a foundational infrastructure in drug development [8][9]

Core Viewpoint - The efficiency of Chinese innovative pharmaceutical companies in research and development is putting pressure on American firms, leading to a shift in strategy where multinational companies are cutting internal R&D budgets to invest in Chinese companies' pipelines [1][7]. Group 1: JPM Conference Insights - The 2026 JPM conference saw a significant presence of Chinese innovative pharmaceutical executives and investors, reflecting a positive outlook compared to previous years, with multinational companies openly expressing interest in Chinese assets [2][4]. - Chinese companies are no longer satisfied with merely licensing patents; they seek deeper involvement in clinical development and commercialization in international markets [3][10]. - The FDA's officials acknowledged the R&D efficiency of Chinese companies and suggested using AI to improve approval processes, indicating a more collaborative approach rather than a protectionist stance [3][6]. Group 2: Market Trends and Stock Performance - Following a surge in business development (BD) transactions in 2025, the stock prices of Chinese innovative pharmaceutical companies saw a significant increase, but there was a market correction starting in September 2025, with the Hang Seng Innovation Drug Index dropping over 20% by January 2026 [3][12]. - The participation of seven Chinese pharmaceutical companies in the main stage of JPM is a sign of increasing recognition and influence in the international market [12]. Group 3: Strategic Shifts in Collaboration - There is a growing trend among Chinese pharmaceutical companies to engage in deeper collaborations, such as the NewCo model, which allows for shared operations and deeper partnerships with American firms [10][11]. - American biotech companies are considering establishing NewCo in China to leverage the country's advantages in R&D efficiency and cost [11]. Group 4: Competitive Landscape and Future Outlook - The competitive landscape is shifting, with Chinese companies focusing on unmet clinical needs and exploring new therapeutic areas beyond traditional targets, such as liver diseases [11]. - Multinational companies are actively seeking new opportunities due to impending patent cliffs, with significant interest in mergers and acquisitions to bolster their pipelines [14][15]. - PwC's report indicates that patent expirations could risk $47 billion in drug sales over the next four years, prompting increased acquisition activities in the pharmaceutical sector [16].